Various antitumor antibodies (Ab), such as cetuximab (Ctx; anti-EGFR), trastuzumab (anti-Her2), and rituximab (Rtx; anti-CD20), were conjugated with FITC forming bispecific small molecule Ab-FITC, which redirected anti-FITC-CAR-T cells binding to tumor cells and induced antitumor activity in vitro and in vivo [90]. The gene discussed is ERBB2; the disease is neoplasm.